The Pediatric Malignancies (PE) Program focuses on malignancies unique to children (neuroblastoma, retinoblastoma, diffuse midline gliomas, and medulloblastoma), as well as cancers more common in children than adults: acute lymphoblastic leukemia (ALL), bone sarcomas, and low-grade gliomas (LGG). Pediatric solid tumors, often embryonal in origin, provide opportunities to understand the links between normal development and aberrant signaling in childhood malignancies; to discover therapeutic targets; and to integrate these discoveries into innovative clinical trials. Inherited cancer predispositions, common in pediatric cancers, offer opportunities to uncover genes and proteins that regulate normal growth and are deregulated in cancer. These molecular studies also inform interactions between tumors and the tumor microenvironment in cancer development, understanding the late effects of treatment, and improving the outcome for survivors. The overall goals of the PE Program are (1) to understand the biology of pediatric malignancies and uncover links between normal development and cancer to identify therapeutic targets; and (2) to translate laboratory discoveries into clinical trials, and epidemiological and survivorship studies to improve clinical outcomes for children with cancer. These goals are addressed by undertaking research in four disease-specific themes: Theme 1: Acute leukemia Theme 2: Brain tumors Theme 3: Neuroblastoma Theme 4: Sarcoma and other pediatric solid tumors PE Program: Key Metrics Membership (12 departments, 2 schools) 30 Full 23 Associate 7 Cancer-relevant Funding (direct costs as of $14,090,085 05/31/2017) NCI $4,160,966 30% Peer-reviewed $5,888,503 42% Non-peer-reviewed $4,040,617 29% Cancer-relevant Publications (1/2012-7/2017) 506 Inter-programmatic 201 40% Intra-Programmatic 139 27% High-Impact 184 36% Accruals to Clinical Trials (2016) 188 85 Therapeutic 88 67 Other Interventional 2 5 Non-interventional 98 13
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
| Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
| An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
| Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014 |
| Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160 |
Showing the most recent 10 out of 192 publications
